NCT00601861View on ClinicalTrials.gov

Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

February 13, 2008

Primary Completion Date

June 25, 2008

Study Completion Date

June 25, 2008

Conditions

CancerMalignant Melanoma

Interventions

DRUG

recombinant interleukin-21

Fixed and equal dose for s.c. injection, 3 times weekly

Trial Locations (1)

10119

Novo Nordisk Investigational Site, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY